An interventional study of fluvastatin 10 mg and valsartan 20 mg and placebo in Atherosclerosis, sponsored by University Medical Centre Ljubljana. Completed. Open to male participants aged 40 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-08.
Sponsored by University Medical Centre Ljubljana · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study was designed to test whether short-term treatment with a very low-dose combination of fluvastatin and valsartan could induce improvement of endothelial function, arterial stiffness, vascular inflammation, oxidative stress and expression of protective genes in subjects with moderate cardiovascular risk.
The largest population that suffers from cardiovascular events are subjects at moderate cardiovascular risk. However, no effective and safe preventive treatment is available for this population. This study aimed to investigate whether their arterial wall phenotype could be turned to a preventive direction by low-dose fluvastatin/valsartan combination (low-flu/val).
Twenty males at moderate cardiovascular risk (as classified by SCORE) were blindly randomised into the intervention group (n=10, low-flu/val: 10 mg/20mg) or control group (n=10, placebo). At inclusion and after 30 days of treatment, brachial flow-mediated dilatation (FMD), beta stiffness coefficient, carotid pulse wave velocity (c-PWV), carotid-femoral PWV, reactive hyperaemia index, high-sensitivity C-reactive protein (hs-CRP), interleukin 6, vascular cell adhesion molecule 1, total antioxidant status and expression of several protective genes (SIRT1, mTOR, NF-κB1, NFE2L2, PRKAA1) were followed.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
This study's enrollment of 20 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →University Medical Centre Ljubljana is the lead sponsor of 296 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
Drug: fluvastatin 10 mg and valsartan 20 mg
received placebo for 30 days
Drug: placebo
Drug page: FluvastatinStudies of FluvastatinFluvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Also known as: low-flu/val
brachial flow-mediated dilatation (FMD)
FMD measured by ultrasound on right brachial artery (as result of reactive hyperaemia)
Time frame: 30 days
reactive hyperaemia index (RHI)
RHI measured by Endopat device
Time frame: 30 days
beta stiffness coefficient
assessed by ultrasound employing e-Tracking on right common carotid artery
Time frame: 30 days
carotid pulse wave velocity (c-PWV)
assessed by ultrasound employing e-Tracking on right common carotid artery
Time frame: 30 days
carotid-femoral PWV (cf-PWV)
cf-PWV measured by Sphygmocor device
Time frame: 30 days
high-sensitivity C-reactive protein (hs-CRP)
inflammatory marker
Time frame: 30 days
interleukin 6 (IL-6)
inflammatory marker
Time frame: 30 days
vascular cell adhesion molecule 1 (VCAM1)
inflammatory marker
Time frame: 30 days
total antioxidant status (TAS)
marker of oxidative stress
Time frame: 30 days
gene SIRT1
Hs01009006_m1
Time frame: 30 days
gene mTOR
Hs00234522_m1
Time frame: 30 days
gene NF-kB1
Hs00765730_m1
Time frame: 30 days
gene Nrf2/NFE2L2
Hs00975961_g1
Time frame: 30 days
gene AMPK/PRKAA1
Hs01562315_m1
Time frame: 30 days
brachial flow-mediated dilatation (FMD)
FMD measured by ultrasound on right brachial artery (as result of reactive hyperaemia)
Time frame: 10 weeks after treatment completion
reactive hyperaemia index (RHI)
RHI measured by Endopat device
Time frame: 10 weeks after treatment completion
beta stiffness coefficient
assessed by ultrasound employing e-Tracking on right common carotid artery
Time frame: 10 weeks after treatment completion
carotid pulse wave velocity (c-PWV)
assessed by ultrasound employing e-Tracking on right common carotid artery
Time frame: 10 weeks after treatment completion
carotid-femoral PWV (cf-PWV)
cf-PWV measured by Sphygmocor device
Time frame: 10 weeks after treatment completion
No study locations are listed for this record.
Ran from Sep 2014 to primary completion in Jun 2015, 9 months.
Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 9 months is below that.
Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluvastatin
University Medical Centre Ljubljana →